STOCK TITAN

[Form 4] QUEST DIAGNOSTICS INC Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Quest Diagnostics (DGX): A company officer reported an insider transaction on a Form 4. On 10/21/2025, the SVP, Clinical Solutions acquired 15 shares of common stock at $189.076 per share.

Following this transaction, the reporting person beneficially owns 8,379 shares directly, plus 358 shares indirectly through a trust and 1,635 shares indirectly via the Company’s 401(k) plan.

Per the footnotes, the 15 shares were acquired through a dividend reinvestment plan and are eligible for deferred reporting on Form 5 under Rule 16a-6; the reporting person chose to report them early.

Quest Diagnostics (DGX): Un dirigente dell'azienda ha segnalato una transazione insider su un Form 4. Il 21/10/2025, il SVP, Clinical Solutions ha acquisito 15 azioni di azioni ordinarie a $189.076 per azione.

A seguito di questa transazione, la persona che segnala detiene beneficiariamente direttamente 8.379 azioni, oltre a 358 azioni indirettamente tramite un trust e 1.635 azioni indirettamente tramite il piano 401(k) della Società.

Secondo le note a piè di pagina, le 15 azioni sono state acquisite tramite un piano di reinvestimento dei dividendi e sono idonee per una segnalazione differita sul Form 5 ai sensi della Regola 16a-6; la persona che segnala ha scelto di riportarle in anticipo.

Quest Diagnostics (DGX): Un ejecutivo de la empresa informó de una operación interna en un Formulario 4. El 21/10/2025, el SVP, Clinical Solutions adquirió 15 acciones de acciones comunes a $189.076 por acción.

Tras esta operación, la persona que reporta posee beneficialmente directamente 8.379 acciones, además de 358 acciones indirectamente a través de un fideicomiso y 1.635 acciones indirectamente mediante el plan 401(k) de la Compañía.

Según las notas a pie de página, las 15 acciones se adquirieron mediante un plan de reinversión de dividendos y son elegibles para reporte diferido en el Formulario 5 bajo la Regla 16a-6; la persona que reporta decidió reportarlas de forma anticipada.

Quest Diagnostics (DGX): 회사 임원이 Form 4에 내부자 거래를 보고했습니다. 2025년 10월 21일, SVP, Clinical Solutions가 15주의 보통주를 주당 $189.076에 취득했습니다.

이번 거래 이후, 보고자 황은 직접적으로 8,379주를 소유하고 있으며, 트러트(신탁)를 통해 간접적으로 358주, 그리고 회사의 401(k) 플랜을 통해 간접적으로 1,635주를 보유하고 있습니다.

주석에 따르면 15주는 배당 재투자 계획을 통해 취득되었으며 제5호 양식의 Rule 16a-6에 따라 이연 보고 대상이 될 수 있습니다. 보고자는 이를 조기에 보고하기로 선택했습니다.

Quest Diagnostics (DGX) : Un dirigeant de la société a signalé une transaction d'initié sur Form 4. Le 21/10/2025, le SVP, Clinical Solutions a acquis 15 actions ordinaires à $189.076 par action.

À la suite de cette transaction, la personne déclarante détient directement 8.379 actions, ainsi que indirectement par le biais d'un trust 358 actions et indirectement via le plan 401(k) de la Société 1.635 actions.

Selon les notes de bas de page, les 15 actions ont été acquises par le biais d'un Plan de réinvestissement des dividendes et sont éligibles à un reporting différé sur le Form 5 en vertu de la Règle 16a-6 ; la personne déclarant a choisi de les déclarer plus tôt.

Quest Diagnostics (DGX): Ein Firmenverantwortlicher meldete eine Insider-Transaktion auf einem Formular 4. Am 21.10.2025 hat der SVP, Clinical Solutions 15 Aktien normaler Stammaktien zu einem Kurs von $189.076 pro Aktie erworben.

Nach dieser Transaktion besitzt die meldende Person direkt 8.379 Aktien, außerdem indirekt über einen Trust 358 Aktien und indirekt über den 401(k)-Plan des Unternehmens 1.635 Aktien.

Wie in den Fußnoten angegeben, wurden die 15 Aktien durch einen Dividendeneinzahlungs-Plan erworben und sind gemäß Regel 16a-6 für eine deferred Reporting auf Form 5 berechtigt; die meldende Person wählte es, sie frühzeitig zu melden.

Quest Diagnostics (DGX): أفاد موظف مسؤول في الشركة بصفقة داخلية في نموذج 4. في 21/10/2025، اشترى نائب الرئيس الأول للحلول السريرية 15 سهماً من الأسهم العادية بسعر $189.076 للسهم.

بعد هذه المعاملة، يمتلك الشخص المبلغ عنه فائدة مباشرة قدرها 8.379 سهماً، بالإضافة إلى 358 سهماً بشكل غير مباشر من خلال وصية و 1.635 سهماً بشكل غير مباشر عبر خطة 401(k) للشركة.

وفقاً للحواشي، تم اكتساب الـ15 سهماً من خلال خطة إعادة استثمار الأرباح وهي مؤهلة للإبلاغ المؤجل في النموذج 5 بموجب القاعدة 16a-6؛ اختار الشخص المبلغ عنه الإبلاغ عنها مبكراً.

Positive
  • None.
Negative
  • None.

Quest Diagnostics (DGX): Un dirigente dell'azienda ha segnalato una transazione insider su un Form 4. Il 21/10/2025, il SVP, Clinical Solutions ha acquisito 15 azioni di azioni ordinarie a $189.076 per azione.

A seguito di questa transazione, la persona che segnala detiene beneficiariamente direttamente 8.379 azioni, oltre a 358 azioni indirettamente tramite un trust e 1.635 azioni indirettamente tramite il piano 401(k) della Società.

Secondo le note a piè di pagina, le 15 azioni sono state acquisite tramite un piano di reinvestimento dei dividendi e sono idonee per una segnalazione differita sul Form 5 ai sensi della Regola 16a-6; la persona che segnala ha scelto di riportarle in anticipo.

Quest Diagnostics (DGX): Un ejecutivo de la empresa informó de una operación interna en un Formulario 4. El 21/10/2025, el SVP, Clinical Solutions adquirió 15 acciones de acciones comunes a $189.076 por acción.

Tras esta operación, la persona que reporta posee beneficialmente directamente 8.379 acciones, además de 358 acciones indirectamente a través de un fideicomiso y 1.635 acciones indirectamente mediante el plan 401(k) de la Compañía.

Según las notas a pie de página, las 15 acciones se adquirieron mediante un plan de reinversión de dividendos y son elegibles para reporte diferido en el Formulario 5 bajo la Regla 16a-6; la persona que reporta decidió reportarlas de forma anticipada.

Quest Diagnostics (DGX): 회사 임원이 Form 4에 내부자 거래를 보고했습니다. 2025년 10월 21일, SVP, Clinical Solutions가 15주의 보통주를 주당 $189.076에 취득했습니다.

이번 거래 이후, 보고자 황은 직접적으로 8,379주를 소유하고 있으며, 트러트(신탁)를 통해 간접적으로 358주, 그리고 회사의 401(k) 플랜을 통해 간접적으로 1,635주를 보유하고 있습니다.

주석에 따르면 15주는 배당 재투자 계획을 통해 취득되었으며 제5호 양식의 Rule 16a-6에 따라 이연 보고 대상이 될 수 있습니다. 보고자는 이를 조기에 보고하기로 선택했습니다.

Quest Diagnostics (DGX) : Un dirigeant de la société a signalé une transaction d'initié sur Form 4. Le 21/10/2025, le SVP, Clinical Solutions a acquis 15 actions ordinaires à $189.076 par action.

À la suite de cette transaction, la personne déclarante détient directement 8.379 actions, ainsi que indirectement par le biais d'un trust 358 actions et indirectement via le plan 401(k) de la Société 1.635 actions.

Selon les notes de bas de page, les 15 actions ont été acquises par le biais d'un Plan de réinvestissement des dividendes et sont éligibles à un reporting différé sur le Form 5 en vertu de la Règle 16a-6 ; la personne déclarant a choisi de les déclarer plus tôt.

Quest Diagnostics (DGX): Ein Firmenverantwortlicher meldete eine Insider-Transaktion auf einem Formular 4. Am 21.10.2025 hat der SVP, Clinical Solutions 15 Aktien normaler Stammaktien zu einem Kurs von $189.076 pro Aktie erworben.

Nach dieser Transaktion besitzt die meldende Person direkt 8.379 Aktien, außerdem indirekt über einen Trust 358 Aktien und indirekt über den 401(k)-Plan des Unternehmens 1.635 Aktien.

Wie in den Fußnoten angegeben, wurden die 15 Aktien durch einen Dividendeneinzahlungs-Plan erworben und sind gemäß Regel 16a-6 für eine deferred Reporting auf Form 5 berechtigt; die meldende Person wählte es, sie frühzeitig zu melden.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
KUPPUSAMY KARTHIK

(Last) (First) (Middle)
500 PLAZA DRIVE
C/O QUEST DIAGNOSTICS INC

(Street)
SECAUCUS NJ 07094

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, Clinical Solutions
3. Date of Earliest Transaction (Month/Day/Year)
10/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/21/2025 A V 15(1) A $189.076 8,379(2) D
Common Stock 358 I By Trust
Common Stock 1,635(3) I 401(k)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
2. The amount includes exempt purchases made under the Company's stock purchase plan since the date of the reporting person's last filing on Form 4.
3. These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under the Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.
Remarks:
Sean D. Mersten, Attorney in Fact for Karthik Kuppusamy 10/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Quest Diagnostics Inc

NYSE:DGX

DGX Rankings

DGX Latest News

DGX Latest SEC Filings

DGX Stock Data

20.38B
110.74M
0.4%
99.16%
3.8%
Diagnostics & Research
Services-medical Laboratories
Link
United States
SECAUCUS